AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30579860 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (at-home bleaching protocol; 4h/d×7)
Number of subjects: 126
Study 30579860 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide (in-office bleaching protocol; 20min×3)
Number of subjects: 126
Study 30579860 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-metallic stained lesions (G1, G2, G3)
Number of subjects: 126
Study 30579860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stained lesions (G4, G5, G6)
Number of subjects: 126
Study 30579860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching treatment, G1 and G4)
Number of subjects: 126
Study 28176424 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP-guided HF therapy using the CardioMEMS™ HF system
Number of subjects: 0
Study 28176424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28176424 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP-guided HF therapy using the CardioMEMS™ HF system with estimated staff time included
Number of subjects: 0
Study 28485289 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF)
Number of subjects: 71
Study 28485289 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BP RF)
Number of subjects: 71
Study 25098195 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant feedback group
Number of subjects: 62
Study 25098195 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feedback group
Number of subjects: 62
Study 25098195 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 21717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise intensity
Number of subjects: 13
Study 21717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exercise intensity
Number of subjects: 13
Study 21717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Very heavy exercise intensity
Number of subjects: 13
Study 21717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake (VO(2peak))
Number of subjects: 13
Study 21717119 — intervention group
Group type: EXPERIMENTAL
Intervention: VO(2) kinetics at any exercise intensity
Number of subjects: 13
Study 19216650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 18
Study 19216650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NPRIs)
Number of subjects: 18
Study 17690922 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 41
Study 17690922 — intervention group
Group type: EXPERIMENTAL
Intervention: Access flap (AF)
Number of subjects: 41
Study 17690922 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 41
Study 17690922 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 41
Study 17690922 — intervention group
Group type: COMPARATOR
Intervention: Interproximal sites
Number of subjects: 41
Study 15372416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 100 mg after each dialysis session
Number of subjects: 61
Study 15372416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVAA)
Number of subjects: 61
Study 11472293 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural washout with twice the volume of 2% mepivacaine (group 2x)
Number of subjects: 30
Study 11472293 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural washout with four times the volume of 2% mepivacaine (group 4x)
Number of subjects: 30
Study 11472293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no washout)
Number of subjects: 30
Study 9671364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IMN) Impact (Novartis Nutrition)
Number of subjects: 390
Study 7851275 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg/day for 4 weeks
Number of subjects: 28
Study 7851275 — intervention group
Group type: COMPARATOR
Intervention: pravastatin
Number of subjects: 28
Study 2801640 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 40
Study 2801640 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 40
Study 1095630 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric oxygenation (97% oxygen + 3% carbon dioxide)
Number of subjects: 7
Study 1095630 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (control group)
Number of subjects: 7
Study 30316113 — intervention group
Group type: EXPERIMENTAL
Intervention: Misattribution of arousal procedure
Number of subjects: 0
Study 27014755 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee + polyethylene glycol + ascorbic acid (750 mL, twice)
Number of subjects: 0
Study 27014755 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol + ascorbic acid (1-L, twice)
Number of subjects: 0
Study 24887797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (range 0 mm)
Number of subjects: 628
Study 24887797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (range 5 mm)
Number of subjects: 628
Study 24887797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (range 10 mm)
Number of subjects: 628
Study 24887797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (range 15 mm)
Number of subjects: 628
Study 24887797 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 628
Study 22734483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver nylon wound dressing
Number of subjects: 0
Study 22734483 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 0
Study 19875683 — intervention group
Group type: EXPERIMENTAL
Intervention: %CSA(<5)
Number of subjects: 79
Study 19875683 — intervention group
Group type: EXPERIMENTAL
Intervention: DL(CO) % predicted
Number of subjects: 79
Study 19875683 — intervention group
Group type: EXPERIMENTAL
Intervention: %CSA(5-10)
Number of subjects: 79
Study 18095148 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuEpo targeting at Hb >= 13.0 g/dL
Number of subjects: 31
Study 15380964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 185
Study 15380964 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin microemulsion
Number of subjects: 185
Study 11153973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 22
Study 9847656 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lumbar epidural morphine (2 to 4 mg during anesthetic induction)
Number of subjects: 20
Study 9847656 — intervention group
Group type: COMPARATOR
Intervention: Postincisional lumbar epidural morphine (2 to 4 mg upon excision of tissue)
Number of subjects: 20
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRw9 phenotype and HLA-Bw61/DRw9 haplotype
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR4 phenotype and Bw54/DR4 haplotype
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: DR4 phenotype
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRw9/DR4 genotype
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gm phenotype of g and gft
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-F phenotype
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA prevalence
Number of subjects: 159
Study 7859638 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies prevalence
Number of subjects: 159
Study 2684134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment
Number of subjects: 24
Study 2684134 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioural treatment
Number of subjects: 24
Study 2684134 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient management (Control)
Number of subjects: 24
Study 30412514 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation (20 minutes, 1.5 mA)
Number of subjects: 24
Study 30412514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation (20 minutes, 1.5 mA)
Number of subjects: 24
Study 30412514 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (20 minutes, 1.5 mA)
Number of subjects: 24
Study 31973579 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour on Day 3
Number of subjects: 51
Study 30385281 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-985 with sodium taurocholate >4 mM
Number of subjects: 0
Study 30385281 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-985 with vitamin E D‐alpha‐tocopherol polyethylene glycol 1000 succinate
Number of subjects: 0
Study 30385281 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro characterization with surfactants
Number of subjects: 0
Study 29068592 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (30 mg per day for 8 weeks)
Number of subjects: 34
Study 29068592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29068592 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Crocin and Placebo
Number of subjects: 34
Study 25624430 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) and Letrozole (2.5 mg daily)
Number of subjects: 38
Study 24312709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Liquid Diet (CLD)
Number of subjects: 801
Study 24312709 — intervention group
Group type: COMPARATOR
Intervention: Regular Diet (RD)
Number of subjects: 801
Study 20622160 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) diagnostic criteria
Number of subjects: 5735
Study 20622160 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA(1c) of 6.0-6.4%
Number of subjects: 5735
Study 20622160 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 5735
Study 20622160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of diabetes
Number of subjects: 5735
Study 19366302 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir)
Number of subjects: 0
Study 19366302 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 16873908 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 16873908 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 0
Study 16873908 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 0
Study 16873908 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 0
Study 15387400 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE score of 4
Number of subjects: 277
Study 15387400 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational drug use
Number of subjects: 277
Study 15387400 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anti-social personality disorders
Number of subjects: 277
Study 15387400 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of childhood conduct disorder
Number of subjects: 277
Study 11524354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine added to mepivacaine (50 microg) for median and musculocutaneous nerves
Number of subjects: 58
Study 11524354 — intervention group
Group type: COMPARATOR
Intervention: Plain mepivacaine 1.5% (Control group)
Number of subjects: 58
Study 9240902 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 100
Study 9240902 — intervention group
Group type: COMPARATOR
Intervention: Conventional lancet
Number of subjects: 100
Study 8236402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 30 days
Number of subjects: 104
Study 8236402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 15 days
Number of subjects: 104
Study 8236402 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg for 30 days
Number of subjects: 104
Study 8236402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg for 30 days and 20 mg/kg for 15 days
Number of subjects: 104
Study 3122247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg oral dose)
Number of subjects: 6
Study 3122247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0.2 mg/kg IV injection)
Number of subjects: 6
Study 3122247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem pretreatment
Number of subjects: 6
Study 31444210 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive for breastfeeding intervention over a 6-month period
Number of subjects: 10010
Study 31444210 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 10010
Study 31444210 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive for breastfeeding intervention
Number of subjects: 10010
Study 28855345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) plus usual care
Number of subjects: 500
Study 28855345 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study 27501767 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel (bevacizumab 10 mg/kg on days 1 and 15 plus paclitaxel 90 mg/m² on days 1, 8, and 15 every 4 weeks)
Number of subjects: 531
Study 27501767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine (bevacizumab 15 mg/kg on day 1 plus capecitabine 1000 mg/m² twice daily on days 1-14 every 3 weeks)
Number of subjects: 531
Study 27501767 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 531
Study 27501767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine
Number of subjects: 531
Study 24477043 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) combined with a protein-enriched diet facilitated through lean red meat (∼160 g cooked, 6 days/week)
Number of subjects: 100
Study 24477043 — intervention group
Group type: COMPARATOR
Intervention: Control PRT (1 serving pasta or rice/day)
Number of subjects: 100
Study 23121374 — intervention group
Group type: EXPERIMENTAL
Intervention: cinacalcet
Number of subjects: 3883
Study 23121374 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3883
Study 20418480 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW) - 2 drinks
Number of subjects: 12
Study 20418480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) - 2 drinks
Number of subjects: 12
Study 20418480 — intervention group
Group type: COMPARATOR
Intervention: Water - 1 drink
Number of subjects: 12
Study 18697376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac rectal suppositories (50 mg, two tablets)
Number of subjects: 72
Study 18697376 — intervention group
Group type: COMPARATOR
Intervention: Placebo rectal suppositories (two look-alike tablets)
Number of subjects: 72
Study 15041587 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral dextromethorphan 30 mg
Number of subjects: 76
Study 15041587 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 76
Study 11735011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg and metronidazole 500 mg
Number of subjects: 61
Study 11735011 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous prophylaxis
Number of subjects: 61
Study 9428917 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide 600 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., fluorouracil 600 mg/m2 i.v.)
Number of subjects: 117
Study 9428917 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-CAF (DES 1 mg orally days 1-3, CAF on day 4)
Number of subjects: 117
Study 8249869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet
Number of subjects: 10
Study 8249869 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet
Number of subjects: 10
Study 8249869 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet
Number of subjects: 10
Study 8249869 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 10
Study 8249869 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 10
Study 3436030 — intervention group
Group type: EXPERIMENTAL
Intervention: F-sterilized dialysers
Number of subjects: 10
Study 3436030 — intervention group
Group type: EXPERIMENTAL
Intervention: New dialysers sterilized by ethylene oxide (not F)
Number of subjects: 10
Study 3436030 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 10
Study 3436030 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-prick tests with F
Number of subjects: 10
Study 3436030 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST to F
Number of subjects: 10
Study 30673725 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/day) for 20 consecutive days
Number of subjects: 11
Study 30673725 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 consecutive days
Number of subjects: 11
Study 29873905 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light source
Number of subjects: 28
Study 29873905 — intervention group
Group type: COMPARATOR
Intervention: Blue light source
Number of subjects: 28
Study 26588214 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message reminders
Number of subjects: 0
Study 26588214 — intervention group
Group type: COMPARATOR
Intervention: No text message reminders (Control)
Number of subjects: 0
Study 24506498 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 2 weeks (Q2W)
Number of subjects: 355
Study 24506498 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa once monthly (QM)
Number of subjects: 355
Study 24506498 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Q2W and QM
Number of subjects: 355
Study 23135654 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcannula
Number of subjects: 95
Study 23135654 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic needle
Number of subjects: 95
Study 19714379 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-night study
Number of subjects: 400
Study 19714379 — intervention group
Group type: COMPARATOR
Intervention: Dual-night study
Number of subjects: 400
Study 16996583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur‐Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV weekly on day 1 concurrent with standard radiotherapy (Group A)
Number of subjects: 469
Study 16996583 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone concurrent with standard radiotherapy (Group B)
Number of subjects: 469
Study 15498381 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries
Number of subjects: 42
Study 15498381 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant platinum-based combination chemotherapy (control)
Number of subjects: 42
Study 11089279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 60
Study 11089279 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 60
Study 9030968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CyA)
Number of subjects: 102
Study 9030968 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (GnRHA)
Number of subjects: 102
Study 9030968 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 102
Study 8295363 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34
Number of subjects: 54
Study 8295363 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41
Number of subjects: 54
Study 8295363 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 and PhXA41 (combined)
Number of subjects: 54
Study 3107378 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate as the sole anticoagulant for periods of 2 months
Number of subjects: 6
Study 3107378 — intervention group
Group type: COMPARATOR
Intervention: Heparin as an anticoagulant
Number of subjects: 6
Study 31188694 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (1.2 g CHO·kg body mass‐1)
Number of subjects: 10
Study 31188694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 29178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg in fed state
Number of subjects: 106
Study 29178442 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib 80 mg in fasted state
Number of subjects: 106
Study 29178442 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg plus osimertinib 80 mg
Number of subjects: 106
Study 29178442 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib 80 mg alone
Number of subjects: 106
Study 28197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.2 mg
Number of subjects: 165
Study 28197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.3 mg
Number of subjects: 165
Study 28197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.4 mg
Number of subjects: 165
Study 28197932 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin doses (0.2, 0.3, 0.4 mg)
Number of subjects: 165
Study 25908010 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 181
Study 25908010 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 181
Study 23890595 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 200mg
Number of subjects: 41
Study 23890595 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 300mg
Number of subjects: 41
Study 23890595 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly 400mg
Number of subjects: 41
Study 23890595 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole once-monthly (any dose)
Number of subjects: 41
Study 21689363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 414
Study 21689363 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 414